Current and future potential roles of the platinum drugs in the treatment of ovarian cancer

Annals of Oncology

Volumn 12, Issue 9, 2001, Pages 1195-1203

  Piccart, M J ^a   Lamb, H ^b   Vermorken, J B ^c  

^a JULES BORDET INSTITUTE   (Belgium)

^b Rx Communications Ltd   (United Kingdom)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Disease management; Ovarian cancer; Platinum drugs; Platinum resistance; Review; Tolerability

Indexed keywords

ALTRETAMINE; AMIFOSTINE; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; BBR 3464; CARBOPLATIN; CISPLATIN; CISPLATIN DERIVATIVE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; GLUTATHIONE; NAVELBINE; NEDAPLATIN; OXALIPLATIN; PACLITAXEL; SATRAPLATIN; SEROTONIN 3 ANTAGONIST; TOPOTECAN;

ADVANCED CANCER; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; EAR DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GYNECOLOGIC SURGERY; HEALTH CARE COST; HUMAN; IN VITRO STUDY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; OVARY CANCER; PRIORITY JOURNAL; REVIEW; URINARY TRACT DISEASE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS;

EID: 0034777823     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012259625746     Document Type: Review

References (71)

1. Chemotherapy for advanced ovarian cancer: Overview of randomized trials
2. Paclitaxel/carboplatin for the initial treatment of advanced ovarian cancer
3. Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials
4. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses of individual patient data from 37 randomised trials
5. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
6. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results
7. Chemotherapy for ovarian cancer - A consensus statement on standard practice
8. Advanced epithelial ovarian cancer: 1998 consensus statements
9. Update of the NCCN ovarian cancer practice guidelines
10. Platinum alone for chemotherapy for ovarian cancer?
11. First-line chemotherapy for advanced ovarian cancer: Paclitaxel, cisplatin and the evidence
12. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A Gynecologic Oncology Group study
13. ICON2: Randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer
14. ICON2 trial
15. ICON2 trial
16. The role of anthracyclines in epithelial ovarian cancer
17. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis
18. Randomised trial of paclitaxel (PTX) and carboplatin (CBDCA) vs. a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin & cisplatin): The Third International Collaborative Ovarian Neoplasm Study (ICON3)
19. Cisplatin/paclitaxel vs. carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Trial
20. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer
21. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) vs. carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): A Gynecologic Oncology Group trial (GOG 158)
22. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer
23. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer
24. The Gynecologic Oncology Group experience in ovarian cancer
25. Synergistic interaction between cisplatin and gemcitabine in vitro
26. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group Study
27. Salvage therapy for ovarian cancer
28. Second-line treatment of ovarian cancer
29. Extending the platinum-free interval in recurrent ovarian cancer: The role of topotecan in second-line chemotherapy
30. Clinical perspectives on platinum resistance
31. Comparative adverse effect profiles of platinum drugs
32. Clinical pharmacokinetics and administration of established platinum drugs
33. Paclitaxel plus carboplatin in the treatment of ovarian cancer
34. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin
35. Initial control of chemotherapy-induced nausea and vomiting in patient quality of life
36. Antiemetic therapy
37. 3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting
38. Patient perceptions of the side-effects of chemotherapy: The influence of 5HT3 antagonists
39. Carboplatin vs. cisplatin in solid tumours: An analysis of the literature
40. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects
41. Approaches to managing carboplatin-induced thrombocytopenia: Focus on the role of amifostine
42. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
43. Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: Relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity
44. Preclinical perspectives on platinum resistance
45. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines
46. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistance to cisplatin
47. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cell lines
48. p53 and chemosensitivity
49. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma
50. Chemotherapy resistance in ovarian cancer: New molecular perspective
51. Drug resistance in ovarian cancer: From the laboratory to the clinic
52. New developments and approaches in the platinum arena
53. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update
54. Oxaliplatin: A review of preclinical and clinical studies
55. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group
56. Multicentric phase II-III trial of oxaliplatin (LOHP) vs. cisplatin (P) both in association with cyclophosphamide (C) in the treatment of advanced ovarian cancer (AOC): Toxicity efficacy results
57. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers
58. Successful treatment with nedaplatin in patients with ovarian cancer that recurred after platinum-containing chemotherapy: Report of two cases
59. Phase I study and pharmacological analysis of cis-diammine(glycolato) platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion
60. Ototoxicity of cis-diammine glycolato platinum, 254-S
61. Preclinical antitumour evaluation of bis-acetato-ammine-dichoro-cyclohexylamine platinum(IV): An orally active platinum drug
62. A phase I and pharmacology study of an oral platinum complex, JM216: Dose-dependent pharmacokinetics with single-dose administration
63. A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: Hypersensitivity of p53-mutant human tumour xenografts
64. BBR 3464: A novel triplatinum complex, exhibiting a preclinical profile of antitumour efficacy different from cisplatin
65. Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex
66. Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy
67. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473
68. Preclinical combination studies in human ovarian carcinoma cell lines with the novel platinum complex ZD0473 (cis-amminedichloro [2-methylpyridine] platinum [II]) and paclitaxel
69. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: In vitro activity, toxicology, and pharmacokinetics in mice
70. Preclinical and clinical overview of the novel platinum complex, ZD0473 (cis-amminedichloro [2-methylpyridine] platinum[II]) [poster]
71. ZD0473 phase II monotherapy trial in second-line ovarian cancer